We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+76.09%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$487M
AUM Growth
+$180M
Cap. Flow
-$10.2M
Cap. Flow %
-2.09%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IMDZ
Immune Design Corp.
IMDZ
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$387M 79.39%
4,780,188
– –
IMDZ
2
DELISTED
Immune Design Corp.
IMDZ
$41M 8.41%
1,983,858
-430,182
-18% -$10.2M
AGRX
3
DELISTED
Agile Therapeutics
AGRX
$40.1M 8.24%
2,334
– –
ANTH
4
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$16.4M 3.36%
237,500
– –
ZSAN
5
DELISTED
Zosano Pharma Corporation
ZSAN
$1.67M 0.34%
328
– –
SVRA icon
6
Savara
SVRA
$1.08B
$1.25M 0.26%
36,455
– –

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q2 2015 Portfolio in Review

As of Q2 2015, ProQuest Associates IV held 6 positions worth $487M, up 59% from $307M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2015: portfolio turnover was 0%. ProQuest Associates IV opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's biggest Q2 2015 reduction was Immune Design Corp., cutting an estimated $10.2M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $487M portfolio in Q2 2015.
  • ProQuest Associates IV opened 0 new positions and closed 0 in Q2 2015.
  • ProQuest Associates IV's portfolio value rose 59% quarter-over-quarter to $487M.

Based on ProQuest Associates IV's 13F filing for Q2 2015, filed 14 Aug 2015.